活性氧介导抗肿瘤前药的研究进展

Recent advances of reactive oxygen species (ROS)-triggered antitumor prodrugs

活性氧(reactive oxygen species,ROS)的异常升高与多种疾病相关,包括癌症、炎症和神经退行性疾病等,而正常细胞中ROS含量则受到严格调控以确保细胞内的氧化还原稳态。鉴于这种非致病性组织与病理组织之间的ROS水平的差异,越来越多针对于ROS的前药策略被开发并用于ROS相关疾病的精准诊断以及靶向治疗。本文作者综述了近年来由ROS介导的抗肿瘤前药的研究进展,旨在总结ROS相关的新化学实体研发现状,并发掘其在临床治疗中的应用价值。

The abnormal increase of reactive oxygen species (ROS) was associated with a variety of diseases,including cancer,inflammation and neurodegenerative diseases,while the content of ROS in norma cells was strictly regulated to ensure intracellular redox homeostasis.In view of the difference of ROS leve betw een non pathogenic tissues and pathological tissues,more and more prodrug strategies for ROS had been developed and used for precise diagnosis and targeted therapy of ROS related diseases.In this paper,the recent progress of ROS-responsive antitumor prodrugs was review ed in order to provide the developmen situations of new ROS-relevant entities and explored their clinical applicability.